Webinar: Gaps in Knowledge of Human Platelet Lysate as a Cell Culture Supplement for Cell Therapy
Tell a Friend About This EventTell a Friend
 

7/17/2019
When: Wednesday, July 17, 2019
9:00 AM
Where: United States
Contact:

« Go to Upcoming Event List  

ISCT Webinar

Gaps in the Knowledge of Human Platelet Lysate as a Cell Culture Supplement for Cell Therapy

CLICK HERE TO REGISTER

 

Chair: Lizette Caballero, BS, MT(ASCP), Senior Supervisor, UCSF Medical Center, USA

Speakers:

  • Karen Bieback, PhD, Professor, Institute for Transfusion Medicine and Immunology, Heidelberg University, Germany
  • Jacques Galipeau, MD, Don and Marilyn Anderson Professor in Oncology, Department of Medicine, University of Wisconsin in Madison, USA

 

About the Webinar:

Fetal bovine serum (FBS) is used as a growth supplement in a wide range of cell culture applications for cell-based research and therapy. However, as a xenogenic product, FBS can potentially transmit prions and adventitious viruses as well as induce undesirable immunological reactions. In addition, the use of bovine fetuses for FBS production raises concerns as society looks for ways to replace animal testing and reduce the use of animal products for scientific purposes − in particular for the manufacture of clinical products intended for human use. Until chemically-defined media are available for these purposes, human platelet lysate (hPL) has been introduced as an attractive alternative for replacing FBS as a cell culture supplement. hPL is a human product that can be produced from outdated platelets avoiding ethical, medical and animal welfare concerns. An increasing number of studies demonstrate that hPL can promote cell growth similarly or even better than FBS in specific cell types. Due to increasing interest in hPL the International Society fer Cell & Gene Therapy (ISCT) and AABB established a joint working group to address its potential. With this webinar, we aim to present an overview of hPL identifying the gaps in information on how hPL is produced and tested and the barriers to its translational use in the production of clinical grade cell therapy products.

Learning Objectives: 

  • Classify and evaluate current gaps in knowledge of hPL as cell culture supplement
  • Discuss and propose recommendations for standardization of hPL production

 

© 2019 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy